Sandu Pharmaceuticals Limited submitted a regulatory compliance filing to the Bombay Stock Exchange pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019.
The filing covers three tranches of fund raising through preferential issue of equity shares (private placement):
First Tranche:
- Date of Funds Raising: 31-03-2021 (25% upfront amount of Share Warrants)
- Amount Raised: ₹2,63,79,653
- Quarter Ended: 30 September 2026
- No deviation/variation in fund utilization
- Full amount utilized as per original objects
Second Tranche:
- Date of Funds Raising: 28-02-2022 (75% allotment monies against allotment of 8,89,667 equity shares on conversion of warrants at ₹20.69 per warrant)
- Amount Raised: ₹1,38,05,408
- Quarter Ended: 30 September 2026
- No deviation/variation in fund utilization
- Full amount utilized as per original objects
Third Tranche:
- Date of Funds Raising: 14 July 2022
- Amount Raised: ₹1,31,94,934
- Quarter Ended: 30 September 2026
- No deviation/variation in fund utilization
- Funds Utilized: ₹66,45,748.19
- Unutilized balance remains
Original Objects of Fund Raising:
The company raised funds for:
- Revamping of capital
- Developing marketing infrastructure
- Civil work required for plant and machinery
- Purchase of new/additional plant and machinery
- Working capital requirement of the company
- Investment in technologies
- General corporate purposes
Regulatory Compliance:
- The statement was reviewed by the Audit Committee and approved by the Board
- No comments from auditors regarding any deviations
- No change in terms of contract or objects requiring shareholder approval
Current Status:
As of 30 September 2026, the company has unutilized money lying in an Escrow account with fixed deposits created in the name of the company in Bank of Baroda for utilizing the amount as and when required.
Total Funds Raised Across Three Tranches: ₹5,33,79,995